A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study ID
NCT06153251
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed and/or Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986453 — DRUG
    Specified dose on specified days
  • Fludarabine — DRUG
    Specified dose on specified days
  • Cyclophosphamide — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).

Key Dates

Start date
Jan 23, 2024
Status verified
Mar 2026
Primary completion
May 2, 2030
Completion
May 2, 2030

Study Design

Enrollment
187 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Administration of BMS-986453

Primary Outcome Measure

Number of participants with treatment-emergent adverse events (AEs) [ Time Frame: Up to 4 years ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (13)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Luciano Costa, Site 0001
205-934-9695
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010
MURALI JANAKIRAM, Site 0003
626-201-5710
UCSF Helen Diller Medical Center at Parnassus HeightsSan FranciscoCalifornia94143
Alfred Chung, Site 0011
000-000-0000
Stanford University Medical CenterStanfordCalifornia94305
Surbhi Sidana, Site 0006
650-723-0822
Colorado Blood Cancer InstituteDenverColorado80218
Tara Gregory, Site 0013
720-754-4800
Yale Cancer CenterNew HavenConnecticut06520
Noffar Bar, Site 0005
000-000-0000
Moffitt Cancer CenterTampaFlorida33612
Doris Hansen, Site 0016
601-812-3214
Dana-Farber Cancer InstituteBostonMassachusetts02215
Clifton Mo, Site 0023
202-689-9961
Icahn School of Medicine at Mount SinaiNew YorkNew York10029
Adriana Rossi, Site 0010
646-962-6500
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065
Sham Mailankody, Site 0004
646-608-3712
Local Institution - 0008NashvilleTennessee37203
Site 0008
Tennessee OncologyNashvilleTennessee37203
Jesus Berdeja, Site 0020
615-329-0570
Swedish Medical CenterSeattleWashington98104
Swathi Namburi, Site 0012
206-386-6738

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, ALCity of Hope Comprehensive Cancer Center· Duarte, CAUCSF Helen Diller Medical Center at Parnassus Heights· San Francisco, CAStanford University Medical Center· Stanford, CAColorado Blood Cancer Institute· Denver, COYale Cancer Center· New Haven, CT